

MEMORANDUM

To: All Regional Medical Laboratory, Inc. (RML) Clients
From: Regional Medical Laboratory, Inc.
Ryan Hatley, MHA, C(ASCP)^{CM}, Manager of Chemistry
Caitlin Schein, MD, Clinical Director, RML Central Laboratory Chemistry and LCMS
Departments
Date: March 9, 2018
Subject: **Tumor Marker Re-Baseline and Crossover Studies**

RML is pleased to announce plans to upgrade to the Abbott immunoassay platform in late May 2018. Most testing will not be significantly affected by the change, but please note that tumor marker values may vary between methods. Therefore, it is recommended that clinicians re-establish baseline tumor marker levels for these assays: **AFP, CA 125, CA 15-3, CA 19-9, and CEA**. Results from different assay kits, methods, or laboratories cannot be used interchangeably.

From March 26th through May 21st, RML will assay and report results from both platforms together to allow for re-baselining of patients. During this time, the patient will be charged for only the current assay. We strongly encourage clinicians following patients with serial testing of these markers to have these patients tested during this time for re-baselining.

Additionally, **RML will no longer offer in-house testing of CA 27.29** starting on May 22, 2018. However, both CA 27.29 and CA 15-3 assays use antibodies to measure oncoprotein product of the MUC1 gene, with each corresponding antibody directed at different parts of the molecule. While the actual measure may vary between the CA 27.29 and CA 15-3 assays, there is no strong evidence supporting one assay over the other.

To help clinicians evaluate differences between CA 27.29 and CA 15-3 assays, RML will offer the opportunity to crossover and re-baseline patients currently monitored by the CA 27.29 assay to the CA 15-3 assay from March 26th through May 21st. RML will report results from both the CA 27.29 and CA 15-3 assays during this time, and the patient will be charged for only the CA 27.29 assay.

Tests Included during Rebaseline Period	Mnemonic	Order Code
AFP with AFP Rebase	AFP CENT	3620125
CA 125 with CA 125 Rebase	CA125	2015625
CA 15-3 with CA 15-3 Rebase	CA15-3	2024000
CA 19-9 with CA 19-9 Rebase	CA 19-9	2024050
CEA with CEA Rebase	CEA ABB	4500425
CA 27.29 with CA 15-3 Rebase	CA27.29	2024375

If you have any questions or concerns about this update, please contact Dr. Caitlin Schein or Ryan Hatley at 918-744-2553.